Cargando…

Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reaction in cancer patients treated with several cytotoxic anticancer agents including paclitaxel. Duloxetine, an antidepressant known as a serotonin-noradrenalin reuptake inhibitor, is the only agent that has moderate evid...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiramoto, Shiori, Asano, Hajime, Miyamoto, Tomoyoshi, Takegami, Manabu, Kawabata, Atsufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719717/
https://www.ncbi.nlm.nih.gov/pubmed/34972132
http://dx.doi.org/10.1371/journal.pone.0261473
_version_ 1784624996068360192
author Hiramoto, Shiori
Asano, Hajime
Miyamoto, Tomoyoshi
Takegami, Manabu
Kawabata, Atsufumi
author_facet Hiramoto, Shiori
Asano, Hajime
Miyamoto, Tomoyoshi
Takegami, Manabu
Kawabata, Atsufumi
author_sort Hiramoto, Shiori
collection PubMed
description Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reaction in cancer patients treated with several cytotoxic anticancer agents including paclitaxel. Duloxetine, an antidepressant known as a serotonin-noradrenalin reuptake inhibitor, is the only agent that has moderate evidence for the use to treat painful CIPN. The present retrospective cohort study aimed to analyze risk factors for paclitaxel-induced peripheral neuropathy (PIPN), and investigate ongoing prescription drug use for PIPN in Japan. Female breast and gynecologic cancer patients who underwent paclitaxel-based chemotherapy at a single center in Japan between January 2016 and December 2019 were enrolled in this study. Patients’ information obtained from electronic medical records were statistically analyzed to test possible risk factors on PIPN diagnosis. Patients’ age, total paclitaxel dose, the history of female hormone-related diseases, hypertension and body mass index (BMI), but not additional platinum agents, were significantly associated with increased PIPN diagnosis. Drugs prescribed for PIPN included duloxetine, pregabalin, mecobalamin and Goshajinkigan, a polyherbal medicine, regardless of poor evidence for their effectiveness against CIPN, and were greatly different between breast and gynecologic cancer patients diagnosed with PIPN at the departments of Surgery and Gynecology, respectively. Thus, older age, greater total paclitaxel dose, the history of estrogen-related diseases, hypertension and BMI are considered risk factors for PIPN in paclitaxel-based chemotherapy of female cancer patients. It appears an urgent need to establish a guideline of evidence-based pharmacotherapy for PIPN.
format Online
Article
Text
id pubmed-8719717
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-87197172022-01-01 Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan Hiramoto, Shiori Asano, Hajime Miyamoto, Tomoyoshi Takegami, Manabu Kawabata, Atsufumi PLoS One Research Article Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reaction in cancer patients treated with several cytotoxic anticancer agents including paclitaxel. Duloxetine, an antidepressant known as a serotonin-noradrenalin reuptake inhibitor, is the only agent that has moderate evidence for the use to treat painful CIPN. The present retrospective cohort study aimed to analyze risk factors for paclitaxel-induced peripheral neuropathy (PIPN), and investigate ongoing prescription drug use for PIPN in Japan. Female breast and gynecologic cancer patients who underwent paclitaxel-based chemotherapy at a single center in Japan between January 2016 and December 2019 were enrolled in this study. Patients’ information obtained from electronic medical records were statistically analyzed to test possible risk factors on PIPN diagnosis. Patients’ age, total paclitaxel dose, the history of female hormone-related diseases, hypertension and body mass index (BMI), but not additional platinum agents, were significantly associated with increased PIPN diagnosis. Drugs prescribed for PIPN included duloxetine, pregabalin, mecobalamin and Goshajinkigan, a polyherbal medicine, regardless of poor evidence for their effectiveness against CIPN, and were greatly different between breast and gynecologic cancer patients diagnosed with PIPN at the departments of Surgery and Gynecology, respectively. Thus, older age, greater total paclitaxel dose, the history of estrogen-related diseases, hypertension and BMI are considered risk factors for PIPN in paclitaxel-based chemotherapy of female cancer patients. It appears an urgent need to establish a guideline of evidence-based pharmacotherapy for PIPN. Public Library of Science 2021-12-31 /pmc/articles/PMC8719717/ /pubmed/34972132 http://dx.doi.org/10.1371/journal.pone.0261473 Text en © 2021 Hiramoto et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hiramoto, Shiori
Asano, Hajime
Miyamoto, Tomoyoshi
Takegami, Manabu
Kawabata, Atsufumi
Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan
title Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan
title_full Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan
title_fullStr Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan
title_full_unstemmed Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan
title_short Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan
title_sort risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: a retrospective study in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719717/
https://www.ncbi.nlm.nih.gov/pubmed/34972132
http://dx.doi.org/10.1371/journal.pone.0261473
work_keys_str_mv AT hiramotoshiori riskfactorsandpharmacotherapyforchemotherapyinducedperipheralneuropathyinpaclitaxeltreatedfemalecancersurvivorsaretrospectivestudyinjapan
AT asanohajime riskfactorsandpharmacotherapyforchemotherapyinducedperipheralneuropathyinpaclitaxeltreatedfemalecancersurvivorsaretrospectivestudyinjapan
AT miyamototomoyoshi riskfactorsandpharmacotherapyforchemotherapyinducedperipheralneuropathyinpaclitaxeltreatedfemalecancersurvivorsaretrospectivestudyinjapan
AT takegamimanabu riskfactorsandpharmacotherapyforchemotherapyinducedperipheralneuropathyinpaclitaxeltreatedfemalecancersurvivorsaretrospectivestudyinjapan
AT kawabataatsufumi riskfactorsandpharmacotherapyforchemotherapyinducedperipheralneuropathyinpaclitaxeltreatedfemalecancersurvivorsaretrospectivestudyinjapan